Transforming Growth Factor-β Inhibits Interferon-γ Secretion by Lymphokine-activated Killer Cells Stimulated with Tumor Cells

Neurologia medico-chirurgica

Volumn 36, Issue 11, 1996, Pages 789-795

  Naganuma, Hirofumi ^a   Sasaki, Atsushi ^a   Satoh, Eiji ^a   Nagasaka, Mitsuyasu ^a   Nakano, Shin ^a   Isoe, Shiro ^a   Nukui, Hideaki ^a   Tasaka, Kachio ^b  

^a Yamanashi Medical University   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

glioblastoma; interferon ; lymphokine activated killer cell; transforming growth factor

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL CULTURE; CULTURE MEDIUM; DOSE RESPONSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOKINE ACTIVATED KILLER CELL;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOKINES; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0029907012     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.36.789     Document Type: Article

References (33)

1. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA: An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86: 4544-4548, 1989.
2. Brooks B, Chapman K, Lawry J, Meager A, Rees RC: Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-β1: Effect of addition of exogenous tumour necrosis factor-α and interferon-γ, and measurement of their endogenous production. Clin Exp Immunol 82: 583-589, 1990.
3. Brown PD, Wakefield LM, Levinson AD, Sporn MB: Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, 3. Growth Factors 3: 35-43, 1990.
4. Chong ASF, Scuderi P, Grimes WT, Hersh EM: Tumor targets stimulate IL-2 activated killer cells to produce interferon-γ and tumor necrosis factor. J Immunol 142: 2133-2139, 1989.
5. Espevik T, Figari IS, Ranges GE, Palladino MA: Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-αreciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β2, and recombinant human TGF-β1. J Immunol 140: 2312-2316, 1988.
6. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA: Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 166: 571-576, 1987.
7. Franks AJ, Ellis E: Immunohistochemical localization of tissue plasminogen activator in human brain tumors. Br J Cancer 59: 462-466, 1989.
8. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841, 1982.
9. Hirte HW, Clark DA, O'Connell G, Rusthoven J, Mazurka J: Reversal of suppression of lymphokineactivated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 142: 207-216, 1992.
10. Hurd SD, Johnson MD, Forbes JT, Carty-Dugger TL, Arteaga CL: Neutralizing TGF-β antibodies increase natural killer (NK) cell activity and inhibit human breast cancer cell tumorigenicity in athymic mice. Proceedings of American Association of Cancer Research 33: 80, 1992.
11. Kasid A, Bell GI, Director EP: Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors: Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141: 690-698, 1988.
12. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor-β is an important immunoregulatory protein for human B lymphocytes. J Immunol 137: 3855-3860, 1986.
13. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037-1050, 1986.
14. Kuppner MC, Hamou M-F, Sawamura Y, Bodmer S, de Tribolet N: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71: 211-217, 1989.
15. Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA: The autocrine production of transforming growth factor-β1 during lymphocyte activation: A study with a monoclonal antibody-based ELISA. J Immunol 145: 1415-1422, 1990.
16. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN: Effect of the expression of transforming growth factor-β2 in primary human glio blastoma on immunosuppression and loss of immune surveillance. J Neurosurg 76: 799-804, 1992.
17. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68: 438-448, 1988.
18. Miescher S, Whiteside TL, Moretta L, von Fliedner V: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138: 4004-4011, 1987.
19. Naganuma H, Kimura R, Sasaki A, Fukamachi A, Nukui H, Tasaka K: Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Acta Neurochir (Wien) 99: 157-160, 1989.
20. Naganuma H, Kimura R, Sasaki A, Nukui H, Tasaka K: Analysis of tumor necrosis factor and lymphotoxin secreted by incubation of lymphokine-activated killer cells with tumor cells. Neurol Med Chir (Tokyo) 32: 189-195, 1992.
21. Naganuma H, Sasaki A, Nukui H, Tasaka K: Antiproliferative cytokines secreted by lymphokineactivated killer cells stimulated with tumor cells. J Neurosurg 77: 411-416, 1992.
22. Naganuma H, Sasaki A, Satoh E, Nagasaka M, Nakano S, Isoe S, Tasaka K, Nukui H: Inhibition of tumor necrosis factor-α and -β secretion by lymphokine activated killer cells by transforming growth factor-β. Jpn J Cancer Res 85: 952-957, 1994.
23. Naganuma H, Sasaki A, Satoh E, Sakihama T, Tasaka K, Nukui H: Improved bioassay for the detection of transforming growth factor-β1 and β2 in malignant gliomas. Neurol Med Chir (Tokyo) 34: 143-149, 1994.
24. Nitta T, Sato K, Yagita H, Okumura K, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368-371, 1990.
25. Ranges GE, Figari IS, Espevik T, Palladino MA: Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166: 991-998, 1987.
26. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor β on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916-3920, 1986.
27. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high-dose in terleukin-2 alone. N Engl J Med 316: 889-897, 1987.
28. Sasaki A, Naganuma H, Satoh E, Nagasaka M, Isoe S, Nakano S, Nukui H: Secretion of transforming growth factor-β1 and -β2 by malignant glioma cells. Neurol Med Chir (Tokyo) 35: 423-430, 1995.
29. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor-β: Biological function and chemical structure. Science 233: 532-534, 1986.
30. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 105: 1039-1045, 1987.
31. Takiuchi H, Tada T, Li X-F, Ogata M, Ikeda T, Fujimoto S, Fujiwara H, Hamaoka T: Particular types of tumor cells have the capacity to convert transforming growth factor-β from a latent to an active form. Cancer Res 52: 5641-5646, 1992.
32. Tzeng JJ, Barth RF, Orosz CG: Quantitation of glioma-reactive cytolytic T lymphocyte precursors by means of limiting dilution analysis. J Immunol Methods 146: 177-184, 1999.
33. Yoshida S, Tanaka R, Takai N, Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48: 5011-5016, 1988.